Enfortumab vedotin is an antibody-drug conjugate that delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) to cells expressing Nectin-4. Enfortumab vedotin is FDA approved for bladder cancer.
This is a phase II, open-label, study to evaluate the efficacy, safety and tolerability of Enfortumab vedotin in participants with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma
Accelerate enrollment with targeted advertising campaigns
Step 1: Add a recruitment campaign (optional)
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites
Your plan includes posting your clinical trials on our recruitment portal and mobile apps. Boost your trials with targeted advertising campaigns to reach more participants, faster.
What you get with a targeted campaign
We handle everything: audience targeting, creative development, geo targeting to your site locations, and ongoing optimizations. Qualified participant inquiries flow directly into your dashboard. Inquiries typically begin within a few days and continue throughout the campaign.
Select your study's therapeutic area and indication below. This helps us calculate accurate campaign budget and delivery timelines based on recruitment complexity.
Maximum participant inquiries available for this indication.
Cost per Inquiry
—
Total Campaign Investment
—
Estimated Campaign Duration
—
Timeline varies based on campaign performance and audience targeting.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites